| Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth G Mahlknecht, R Maron, M Mancini, B Schechter, M Sela, Y Yarden Proceedings of the National Academy of Sciences 110 (20), 8170-8175, 2013 | 168 | 2013 |
| EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer M Kedmi, N Ben-Chetrit, C Körner, M Mancini, NB Ben-Moshe, M Lauriola, ... Science signaling 8 (368), ra29-ra29, 2015 | 76 | 2015 |
| Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer N Ben-Chetrit, D Chetrit, R Russell, C Koerner, M Mancini, A Abdul-Hai, ... Science Signaling 8 (360), ra7-ra7, 2015 | 69 | 2015 |
| SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors L Roth, S Srivastava, M Lindzen, A Sas-Chen, M Sheffer, M Lauriola, ... Science signaling 11 (515), eaan0949, 2018 | 53 | 2018 |
| Examination of HER3 targeting in cancer using monoclonal antibodies N Gaborit, A Abdul-Hai, M Mancini, M Lindzen, S Lavi, O Leitner, ... Proceedings of the National Academy of Sciences 112 (3), 839-844, 2015 | 50 | 2015 |
| An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors M Mancini, H Gal, N Gaborit, L Mazzeo, D Romaniello, TM Salame, ... EMBO Molecular Medicine 10 (2), 294-308, 2018 | 48 | 2018 |
| A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways D Romaniello, L Mazzeo, M Mancini, I Marrocco, A Noronha, M Kreitman, ... Clinical Cancer Research 24 (22), 5610-5621, 2018 | 46 | 2018 |
| Inhibition of pancreatic carcinoma by homo-and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 R Maron, B Schechter, M Mancini, G Mahlknecht, Y Yarden, M Sela Proceedings of the National Academy of Sciences 110 (38), 15389-15394, 2013 | 43 | 2013 |
| Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors M Mancini, Y Yarden Seminars in cell & developmental biology 50, 164-176, 2016 | 42 | 2016 |
| Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma EB Mur, S Bernardo, L Papon, M Mancini, E Fabbrizio, M Goussard, ... The Journal of Clinical Investigation 130 (2), 612-624, 2020 | 41 | 2020 |
| Navigator‐3, a modulator of cell migration, may act as a suppressor of breast cancer progression H Cohen‐Dvashi, N Ben‐Chetrit, R Russell, S Carvalho, M Lauriola, ... EMBO molecular medicine 7 (3), 299-314, 2015 | 39 | 2015 |
| Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer M Mancini, N Gaborit, M Lindzen, T Meir Salame, M Dall’Ora, ... Science signaling 8 (379), ra53-ra53, 2015 | 36 | 2015 |
| Efficacy of the CDK4/6 dual inhibitor abemaciclib in EGFR-mutated NSCLC cell lines with different resistance mechanisms to osimertinib S La Monica, C Fumarola, D Cretella, M Bonelli, R Minari, A Cavazzoni, ... Cancers 13 (1), 6, 2020 | 31 | 2020 |
| MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis D Kantar, EB Mur, M Mancini, V Slaninova, YB Salah, L Costa, E Forest, ... Scientific Reports 11 (1), 5752, 2021 | 13 | 2021 |
| Generation and characterization of a new preclinical mouse model of EGFR-driven lung cancer with MET-induced osimertinib resistance M Mancini, QD Thomas, S Bourdel, L Papon, E Bousquet, P Jalta, ... Cancers 13 (14), 3441, 2021 | 7 | 2021 |
| HP1s modulate the S-Adenosyl Methionine synthesis pathway in liver cancer cells M Mancini, L Papon, A Mangé, F Cammas, E Fabbrizio Biochemical Journal 477 (5), 1033-1047, 2020 | 5 | 2020 |
| Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia H Xiong, M Mancini, M Gobert, S Shen, GC Furtado, SA Lira, ... Theranostics 11 (4), 1594, 2021 | 4 | 2021 |
| Odours of cancerous mouse congeners: detection and attractiveness F Gouzerh, B Buatois, MR Hervé, M Mancini, A Maraver, L Dormont, ... Biology Open 11 (4), bio059208, 2022 | 3 | 2022 |
| Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) Y Yarden, M Mancini, N Gaborit US Patent 10,011,659, 2018 | 1 | 2018 |
| MDM2 stabilization of Notch intracellular domain upon DNA damage plays a major role in non-small cell lung carcinoma response to platinum chemotherapy S Bernardo, QD Thomas, M Mancini, A Santos, SF Rasamizafy, ... bioRxiv, 2024.04. 29.591624, 2024 | | 2024 |
